Fujifilm Sonocare has announced CE mark approval for its newest generation of point-of-care ultrasound the X-Porte ultrasound kiosk. X-Porte uses...
The FDA has approved Coagadex (coagulation factor X human), from Bio Products Lab, for hereditary Factor X deficiency. Until this...
Bio Products Laboratory Limited has presented new data from TEN02, the Phase III, prospective study of Coagadex (Coagulation Factor X,...
Philips launches Ingenia Ambition X 1.5T MR with industry-first fully sealed magnet for more productive, helium-free operations. Royal Philips has...
Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for: - Treatment in monotherapy of infantile spasms (West's syndrome). - Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
The FDA has approved the Selenia Dimensions System,from Hologic Inc., the first X-ray mammography device that provides three-dimensional (3-D) images...
The FDA has accepted for filing a supplemental Biologics License Application (BLA) for Coagadex (Coagulation Factor X, Human), from Bio...